MicroRNA-181b regulates endotoxin tolerance by targeting IL-6 in macrophage RAW264.7 cells

Journal of Inflammation (United Kingdom)

Volumn 12, Issue 1, 2015, Pages

  Zhang, Wenjun ^a   Shen, Xiaojun ^a   Xie, Luyang ^c   Chu, Maoping ^b   Ma, Yanmei ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

Author keywords

Endotoxin tolerance; IL 6; LPS; Macrophage; miR 181b

Indexed keywords

ENDOTOXIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MICRORNA; MICRORNA 181B; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; IL 6 GENE; IMMUNE RESPONSE; MACROPHAGE; PROTEIN EXPRESSION; PROTEIN TARGETING; RNA PROCESSING; UPREGULATION;

EID: 84925394396     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/s12950-015-0061-8     Document Type: Article

References (35)

1. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-76.
2. Stabel JR. Host responses to Mycobacterium avium subsp. paratuberculosis: a complex arsenal. Anim Health Res Rev. 2006;7:61-70.
3. Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C, et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine a2a receptors∗. Annu Rev Immunol. 2004;22:657-82.
4. Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine. 1997;9:853-8.
5. Kinjyo I, Hanada T, Inagaki-Ohara K, Mori H, Aki D, Ohishi M, et al. SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity. 2002;17:583-91.
6. Tham DM, Wang Y-X, Rutledge JC. Modulation of vascular inflammation by PPARs. Drug News Perspect. 2003;16:109-16.
7. Gilchrist M, Thorsson V, Li B, Rust AG, Korb M, Kennedy K, et al. Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4. Nature. 2006;441:173-8.
8. Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 2010;79:351-79.
9. Lodish HF, Zhou B, Liu G, Chen C-Z. Micromanagement of the immune system by microRNAs. Nat Rev Immunol. 2008;8:120-30.
10. Quinn EM, Wang J, Redmond HP. The emerging role of microRNA in regulation of endotoxin tolerance. J Leukoc Biol. 2012;91:721-7.
11. Su X, Qian C, Zhang Q, Hou J, Gu Y, Han Y, et al. miRNomes of haematopoietic stem cells and dendritic cells identify miR-30b as a regulator of Notch1. Nat Commun. 2013;4:2903.
12. El Gazzar M, McCall CE. MicroRNAs distinguish translational from transcriptional silencing during endotoxin tolerance. Journal of Biological Chemistry. 2010;285:20940-51.
13. Sun X, Icli B, Wara AK, Belkin N, He S, Kobzik L, et al. MicroRNA-181b regulates NF-kappaB-mediated vascular inflammation. J Clin Invest. 2012;122:1973-90.
14. Liu Y, Chen Q, Song Y, Lai L, Wang J, Yu H, et al. MicroRNA-98 negatively regulates IL-10 production and endotoxin tolerance in macrophages after LPS stimulation. FEBS Lett. 2011;585:1963-8.
15. Li XC L, Li YJ. MicroRNA-146a and Human Disease. Scand J Immunol. 2011;71:227-31.
16. Otero JE, Chen T, Zhang K, Abu-Amer Y. Constitutively Active Canonical NF-kB Pathway Induces Severe Bone Loss in Mice. PLoS One. 2012;7:e38694.
17. Bäckdahl L, Bushell A, Beck S. Inflammatory signalling as mediator of epigenetic modulation in tissue-specific chronic inflammation. Int J Biochem Cell Biol. 2009;41:176-84.
18. Hirst M, Marra MA. Epigenetics and human disease. Int J Biochem Cell Biol. 2009;41:136-46.
19. Wang Q, Fang CH, Hasselgren P-O. Intestinal permeability is reduced and IL-10 levels are increased in septic IL-6 knockout mice. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2001;281:R1013-23.
20. Kishimoto T. The biology of interleukin-6. Blood. 1989;74:1-10.
21. Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, et al. Expression of Angiotensin II and Interleukin 6 in Human Coronary Atherosclerotic Plaques Potential Implications for Inflammation and Plaque Instability. Circulation. 2000;101:1372-8.
22. Tackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus. 2004;13:339-43.
23. Yamakawa Y, Sugita Y, Nagatani T, Takahashi S, Yamakawa T, Tanaka S-i, et al. Interleukin-6 (IL-6) in patients with Behc¸et's disease. J Dermatol Sci. 1996;11:189-95.
24. Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes. 2002;51:3391-9.
25. Klein B, Zhang X-G, Lu Z-Y, Bataille R. Interleukin-6 in human multiple myeloma. Blood. 1995;85:863-72.
26. Alesci S, Martinez PE, Kelkar S, Ilias I, Ronsaville DS, Listwak SJ, et al. Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. Journal of Clinical Endocrinology & Metabolism. 2005;90:2522-30.
27. Strauss S, Bauer J, Ganter U, Jonas U, Berger M, Volk B. Detection of interleukin-6 and alpha 2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients. Laboratory investigation; a journal of technical methods and pathology. 1992;66:223-30.
28. Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC. Interleukin-6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathway. Prostate. 2000;42:239-42.
29. Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1993;52:232-4.
30. Muto T, Okazaki IM, Yamada S, Tanaka Y, Kinoshita K, Muramatsu M, et al. Negative regulation of activation-induced cytidine deaminase in B cells. Proc Natl Acad Sci U S A. 2006;103:2752-7.
31. Slaby O, Lakomy R, Fadrus P, Hrstka R, Kren L, Lzicarova E, et al. MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients. Neoplasma. 2010;57:264-9.
32. Visone R, Veronese A, Rassenti LZ, Balatti V, Pearl DK, Acunzo M, et al. miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood. 2011;118:3072-9.
33. Zhi F, Chen X, Wang S, Xia X, Shi Y, Guan W, et al. The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma. Eur J Cancer. 2010;46:1640-9.
34. Shi L, Cheng Z, Zhang J, Li R, Zhao P, Fu Z, et al. hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells. Brain Res. 2008;1236:185-93.
35. Zhu W, Shan X, Wang T, Shu Y, Liu P. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer. 2010;127:2520-9.